Physician profile
Ashokkumar Ghadia
NPI 1124049234
$15,190.71
in general payments reported to CMS, 2019-2025
69 companies · $2,844 in 2025
The $2,844 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,290 · 2020: $1,625 · 2021: $2,297 · 2022: $1,907 · 2023: $2,167 · 2024: $2,061 · 2025: $2,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,071.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,371.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,876.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,050.14 | 2019-2025 | |
| Lilly USA, LLC | $937.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $683.89 | 2019-2025 | |
| Novo Nordisk INC | $582.31 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.72 | 2019-2024 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $519.01 | 2019-2022 | |
| Amarin Pharma, INC. | $488.08 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $448.29 | 2019-2025 | Gardasil 9, Verquvo, M-M-R II |
| Amgen INC. | $431.01 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $394.71 | 2019-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $373.39 | 2022-2024 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $311.35 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $284.33 | 2020-2021 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashokkumar Ghadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.